NovaBay shares jump on positive PhII catheter solution study

Shares of NovaBay Pharmaceuticals shot up 11% after the Emeryville, CA-based biotech said that a mid-stage study of a new solution to prevent problems for people with indwelling urinary catheters proved successful, paving the way for a late-stage trial. The biotech says the data demonstrated an improved response for the patients whose catheters were irrigated with a solution of auriclosene instead of saline. An estimated 100,000 people in the U.S. rely on these indwelling catheters. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.